Skip to search formSkip to main contentSkip to account menu

PXD101

Known as: PXD 101 
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. PXD101 targets HDAC enzymes, thereby inhibiting tumor… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

belinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Effects of Embryo Aggregation and PXD101 on the In Vitro Development of Mouse Somatic Cell Nuclear Transfer Embryos.
To improve the cloning efficiency of somatic cell nuclear transfer (SCNT) and to establish nuclear transfer embryonic stem cells… 
2015
2015
Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
CONTEXT The influence of the novel heat shock protein 90 (hsp90) inhibitor NVP-AUY922 (AUY922) on anaplastic thyroid carcinoma… 
2014
2014
A general xTCA compliant and FPGA based data processing building blocks for trigger and data acquisition system
This paper describes a general purpose xTCA compliant and FPGA based Data Processing building blocks to be used for trigger and… 
2012
2012
A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520.
e18536 Background: The mechanism of action of histone deacetylase inhibitors (HDACI) in lymphomas is unknown. Loss of major… 
2010
2010
Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
2010
2010
A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients.
2007
2007
A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma
15081 Background: Hepatocellular carcinoma (HCC) is a common cause of cancer morbidity and mortality. It is a highly aggressive… 
2006
2006
A Phase II Study of PXD101 in Advanced Multiple Myeloma.
Background: PXD101 is a small molecule HDAC inhibitor of the hydroxamate class, which demonstrates broad anti-neoplastic activity… 
2005
2005
A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours
3035 BackgroundPXD101 is a novel HDAC inhibitor with potent antiproliferative activity in vitro. PXD101 inhibits tumour growth in… 
2005
2005
A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
3137 Background PXD101 is a novel hydroxamate HDAC inhibitor with potent antiproliferative activity in vitro against many… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)